Recurrent mutations in isocitrate dehydrogenases IDH1 or IDH2 are detected in more than 15% of newly diagnosed AML patients and lead to the production of the oncometabolite (R)-2-hydroxyglutarate (2-HG) [1]. This evidence concerns the gene IDH1 and acute myeloid leukemia.